{"database":"ENA","file_versions":[],"scores":null,"additional":{"omics_type":["Genomics"],"center_name":["MUI","Medical University of Innsbruck, Department of Gynecology and Obstetrics"],"full_dataset_link":["https://www.ebi.ac.uk/ena/browser/view/PRJEB93935"],"long_description":["The identification of novel molecular drivers and the development of new state-of-the-art therapies are critical challenges in ovarian cancer treatment. The present study examined the transcriptomic changes of the dual CDK12/13-inhibitor SR-4835 in platinum-sensitive and platinum-resistant OC cell lines. Ovarian cancer cell lines (A2780, A2780 cis, SK-OV-3, Caov-3, Caov-3 cis) were treated for 24h with 90 nM SR-4835 and transcriptome profiling was performed."],"repository":["ENA"],"additional_accession":[]},"is_claimable":false,"name":"SR-4835 in ovarian cancer","description":"Transcriptomic changes after CDK12/13 inhibition by SR-4835 in ovarian cancer cell lines","dates":{"last_updated":"2025-07-17","first_public":"2025-07-17"},"accession":"PRJEB93935","cross_references":{}}